anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Peptoids are provided which are polymers comprised of monomer units wherein the monomer units include at least some substitute amino acids and may include conventional amino acids. The peptoids can be synthesized in large numbers so as to provide libraries of peptoids which can be screened in order to isolate peptoids of desired biological activity. Although the peptoids may include amino acids, they preferably include only substituted amino acids and are designed in a manner so as to have a particular biological activity. Certain peptoids are designed to mimic as closely as possible the activity of known proteins. Other peptoids are designed so as to have greater or lesser activity than known proteins and may be designed so as to block known receptor sites and/or elicit a desired immunogenic response and thereby act as vaccines. In that the peptoids are comprised of substitute amino acids they can be designed to have structures which natural proteins cannot conform to. A range of different amino acid substitutes are disclosed, as are their methods of synthesis and methods of using such amino acid substitutes in the synthesis of peptoids and peptoid libraries. Methods of screening the libraries in order to obtain desired peptoids of a particular biological activity are also disclosed. The peptoids are preferably linked to a pharmaceutically active drug forming a conjugate with increased binding affinity to a particular biological receptor site.
The invention discloses a liquid embolic agent composition loaded with sodium bicarbonate powder and application thereof. The liquid embolic agent is prepared by mixing anion modified polyethylene-polyvinyl alcohol copolymer (EVOH), solvent, baking soda powder and developer according to a certain proportion. EVOH introduces negative ion groups on a polymer chain by a chemical modification or graft modification method, and the negative ion groups can adsorb and load cationized chemotherapeutic anti-cancer drugs through the interaction of positive and negative charges. The solvent may be dimethyl sulfoxide (DMSO), N-methyl pyrrolidone (NMP), ethanol or a mixture thereof. The developer is micron level metal tantalum powder or iodine containing photographic agent or their mixture. The baking soda can sensitize the ischemic effect of tumor cells, thereby improving the curative effect of embolism. The liquid embolic agent composition can be widely applied to the preparation of drugs for interventional embolization treatment, in particular to the preparation of drugs for transcatheter arterial chemoembolization Treatment (TACE) of liver cancer.
Pharmaceutical compositions having diuretic and circulatory stimulant activity for the treatment of cardiac and circulatory disorders comprise exo-benzylidene adenosine (exo-2\sv, 3\sv-O-benzylidene adenosine) in admixture with a solid pharmaceutical diluent or carrier, with a sterile liquid pharmaceutical diluent or carrier or with a liquid pharmaceutical carrier or diluent containing a sweetening and/or flavouring agent.  The compositions may be administered orally or parenterally in the form of tablets, capsules, dragees, syrups, solutions or suspensions containing conventional excipients. Injectable sterile solutions may contain a buffer (e.g. a citrate, tartrate or phosphate buffer) and polymers with an average molecular weight of 300-500 (e.g. polyethylene oxides) for adjusting the viscosity.  The composition may additionally comprise a cardiac-active glycoside, e.g. digoxin.
Retrograde Autologous Prime of the bypass circuit. To remove 500-900ML of fluid.
Patients receive cabozantinib PO QD. Cycles repeat every 30 days in the absence of disease progression or unacceptable toxicity.
Participants will receive a lumbar SMT technique previously described in the literature and commonly utilized for the treatment of low back pain . The SMT will be performed four times (two times on each side) in a 5-minute period. In addition, the following will be performed: Functional MRI (fMRI), Behavioral: Pain Sensitivity Testing, Questionnaires,Behavioral: Physical Impairment.
Vemurafenib will be given at a dose of 960 mg, orally, 2X a day to all patients. Cobimetinib will be given at a dose of 60mg, orally, 1X a day to all patients for 21 days, then 7 days off, in a 28 day treatment cycle. Patients will be assessed for toxicity every 4 weeks and be restaged for tumor response/progression every 8 weeks until week 48, then every 12 weeks thereafter. Patients will be followed until disease progression.
The dynamic progression of metabolic syndrome (MetS) includes developmental deterioration and reverse recovery; however, the key factors in this bidirectional progression have not been identified. Our study aimed to use the data obtained from the China Health and Retirement Longitudinal Study (CHARLS) and construct a Bayesian network to explore the causal relationship between influential factor and the development and recovery of MetS. Followed up at 4 years, forward progression of MetS occurred in 1543 and reverse recovery of MetS occurred in 1319 of 5581 subjects. Bayesian Networks showed that hyperuricemia and body mass index (BMI) levels directly influenced progression of MetS, and gender, exercise and age play an indirect role through hyperuricemia and BMI levels; high hemoglobin A1c (HbA1c) and BMI levels directly influenced recovery of MetS, and gender and exercise play an indirect role through BMI levels. Bayesian Network inference found that the rate of progression of MetS in subjects with hyperuricemia increases from 36 to 60%, the rate of progression of MetS in subjects with overweight or obese increases from 36 to 41% and the rate of reverse recovery rate of MetS in subjects with high HbA1c decreased from 33 to 20%. Therefore, attention to individuals at high risk of hyperuricemia, high HbA1c levels, and overweight/obesity should be enhanced, with early detection and following healthy behavioral interventions to prevent, control and delay the progression of MetS and its components.
Diabetes education and self-management skills training delivered via 36 bilingual diabetes education newsletters over a 2 year period. The newsletters cover recommended diabetes self-management behaviors including glucose self-monitoring, responding to abnormal blood glucose levels, working effectively with health care providers, medication adherence, foot care, daily physical activity, and reducing fat content of diet. The newsletters also describe behavioral skills of self-monitoring, environmental restructuring, engagement of social support, stress management, and problem-solving skills to facilitate the self-management activities.
Ploidy is relevant to numerous biological phenomena, including development, metabolism, and tissue regeneration. Single-cell RNA-seq and other omics studies are revolutionizing our understanding of biology, yet they have largely overlooked ploidy. This is likely due to the additional assay step required for ploidy measurement. Here, we developed a statistical method to infer ploidy from single-cell ATAC-seq data, addressing this gap. When applied to data from human and mouse cell atlases, our method enabled systematic detection of polyploidy across diverse cell types. This method allows for the integration of ploidy analysis into single-cell studies. Additionally, this method can be adapted to detect the proliferating stage in the cell cycle and copy number variations in cancer cells. The software is implemented as the scPloidy package of the R software and is freely available from CRAN.
PURPOSE: An RTLS tag for real-time management of livestock and a livestock managing system using the same are provided to biochemically test blood of livestock and communicate with an RTLS(Real Time Locating Systems) tag to transmit the test result in real time, thereby checking whether livestock which have diseases exist in real time. CONSTITUTION: A wireless transceiving unit(220) forms a communication channel by a reader and an antenna of an RTLS. A blood gathering unit(250) gathers blood of livestock. A bio sensor(260) measures components in the blood. The bio sensor senses a thermal change and a chemical change of the blood to output an electrical signal. A memory(230) stores identification information of a tag.
There are multiple disorders (each with a unique underlying cause) that result in unusually high circulating levels of FGF23, which in turn result in renal phosphate wasting and reduced (or aberrantly normal in relationship to elevated FGF23) levels of 1,25-dihydroxy vitamin D (1,25\[OH\]2D). Across these disorders the clinical symptoms are similar and often include osteomalacia (and, in children, rickets), muscle weakness, fatigue, bone pain, and fractures. Burosumab has been FDA-approved for one of these disorders, X-linked hypophosphatemia (XLH). In single- and repeat-dose clinical studies in subjects with XLH, subcutaneous (SC) administration of burosumab consistently increased and sustained serum phosphorus levels and tubular reabsorption of phosphate (TRP) and improved radiologic rickets, without a major impact on urine calcium levels. Positive results were also observed in a nonclinical pharmacology model of XLH. It is hypothesized that burosumab may provide clinical benefit in this patient due to the common underlying feature in this patient and in patients with XLH - abnormally elevated FGF23 in the context of low age -adjusted serum phosphorous levels.
Schizophrenia, a multifaceted neuropsychiatric disorder characterized by disruptions in perception, cognition, and behavior, has been associated with neuroinflammatory processes. Emerging research has increasingly recognized the potential involvement of immune-related factors in the pathogenesis of schizophrenia, prompting investigations into biomarkers associated with inflammatory cascades. Among these biomarkers, Eosinophil Cationic Protein (ECP), traditionally known for its role in eosinophil-mediated immune responses, has garnered attention for its putative association with neuroinflammation in schizophrenia. This paper critically examines the current understanding of the role of ECP in schizophrenia. ECP, a cytotoxic protein released by eosinophils, has diverse immunomodulatory effects and has been identified in altered concentrations in individuals with schizophrenia. Studies have reported elevated levels of ECP in peripheral fluids of schizophrenia patients, suggesting a possible link between ECP dysregulation and the inflammatory milieu characteristic of the disorder. Moreover, the potential implications of ECP in neuroinflammatory processes relevant to schizophrenia pathophysiology are discussed. ECP's role in modulating immune responses and its potential impact on neuronal function, synaptic plasticity, and neurotoxicity within the central nervous system (CNS) are considered, highlighting the potential contribution of ECP to the neuroinflammatory mechanisms underlying schizophrenia. In conclusion, while the precise role of ECP in schizophrenia pathogenesis warrants further elucidation, exploring its association with neuroinflammation holds promise in unraveling new biomarkers and therapeutic avenues for managing this complex psychiatric disorder.
The problem to be addressed by the present invention is that of enabling information to be communicated in real time to a seating apparatus user. An information provision system according to the present invention is a system in which a management server provided in the cloud, a sensing device, a seating apparatus user terminal, and an advice provider terminal are connected via a communication network. The management server comprises a communication unit and an advice reception unit, and advice is transmitted to the seating apparatus user terminal upon the advice being received. The management server according to the present invention comprises the communication unit and the advice reception unit, and the advice is transmitted to the seating apparatus user terminal upon the advice being received. The program according to the present invention causes a computer to function as the management server. The storage medium according to the present invention can be read by the computer and has the program stored thereon.
PURPOSE:To obtain a powder material having high far infrared irradiation intensity and excellent deodorizing property by coating the surface of hydrate silicic acid particles with superfine alumina hydrate and specifying the BET specific surface area to a certain value or more. CONSTITUTION:Alkali silicate is neutralized with soluble acid to precipitate nongel type hydrate silicic acid particles. With coexistance of the hydrate silicic acid particles as produced, soluble Al salt soln. is neutralized with NH4OH so that superfine particles of alumina hydrate (<=0.01mu) precipitate and adsorb in a needle-like particle state or a film state on each hydrate silicic acid particle. By this method, the powder material for far infrared irradiation which consists of hydrate silicic acid coated with alumina hydrate can be obtained. The obtd. material has >=200m<2>/g BET specific surface area and <=0.2g/cc apparent density, and can be used for fibers, plastics, coating materials, etc., to give far infrared effect and deodorant effect.
Anti-TROP2 antibody and method for producing the same and anti-TROP2 antibody-drug conjugate provide an antitumor drug having an excellent therapeutic effect, which is excellent in terms of antitumor effect and safety. The present invention provides an anti-TROP2 antibody having CDRH1 comprising the amino acid sequence represented by SEQ ID No. 23, CDRH2 comprising the amino acid sequence represented by SEQ ID No. 24, and CDRH3 comprising the amino acid sequence represented by SEQ ID No. 25 in the heavy chain variable region; and CDRL1 comprising the amino acid sequence represented by SEQ ID No. 26, CDRL2 comprising the amino acid sequence represented by SEQ ID No. 27, and CDRL3 comprising the amino acid sequence represented by SEQ ID No. 28 in the light chain variable region. The anti-TROP2 antibody has a heavy chain variable region comprising an amino acid sequence described in amino acid positions 20 to 140 in SEQ ID NO. 12 and a light chain variable region comprising an amino acid sequence described in amino acid positions 21 to 129 in SEQ ID NO. 18. Alternatively, the anti-TROP2 antibody has a heavy chain comprising an amino acid sequence described in amino acid positions 20 to 470 in SEQ ID NO. 12 and a light chain comprising an amino acid sequence described in amino acid positions 21 to 234 in SEQ ID NO. 18. The anti-TROP2 antibody lacks a lysine residue at the carboxy terminal of the heavy chain. In addition, the method for producing the anti-TROP2 antibody and a functional fragment or modified variant thereof according to the present invention comprises the steps of culturing transformed host cells containing polynucleotide of the anti-TROP2 antibody or polynucleotide vectors of the anti-TROP2 antibody; and purifying the anti-TROP2 antibody from the culture product obtained from the culturing step. The anti-TROP2 antibody is used to selectively deliver the anti-tumor compound to cancer cells.
Compositions and methods for diagnosing, treating and/or preventing cancers characterized by CDH 17 overexpression based on the detection of CDH 17 or the use of CDH 17 as a target for therapeutic intervention or prophylactic intervention are provided. Methods for diagnosing and /or monitoring liver cancers using the expressing of CDH 17 involve detecting and/or quantitating the CDH 17 protein or encoding nucleic acids (DNA or RNA) in a biological sample such as urine from the subject. The presence of CDH 17 molecule in liver tissues denotes the incidence of liver cancer. The methods can be used to detect either soluble or truncated forms of CDH 17 by using antibodies specific for the unique regions spanning domains 1 and 2 (D1-D2) of the truncated and secreted CDH 17. Methods for treating liver cancers using CDH 17 as a target and of sensitizing cells with aberrant expression of CDH 17 have also been developed. The methods include suppression or knockdown of the expression of CDH 17 by administering an effective amount of a CDH 17 inhibitor. The suppression or knockdown of CDH 17 reduces in size liver tumors derived from tumor cells that exhibit an increased expression of CDH 17 and renders liver tumor cells more sensitive to certain chemotherapeutic drugs, such as Taxol, Epirubicin, and Carboplatin, and p53-based gene therapy.
Perceptual surfaces is a therapeutic system that is based on the interaction between the patient's back or painful area and a support surface, composed of small latex cones with various dimensions (height: 3-8 cm; base diameter: 2-4 cm) and elasticities. The inferior bases of these cones are applied to a rigid wood surface using elastic strips; usually, over 100 cones are used for each session. Patients were asked to lie down supine on the surface that was formed by the smoothed apex of these cones, creating reaction forces to the patient's weight, generated by the interaction with the cones.
The SilverCloud interventions comprise of 8 modules of evidence-based CBT which have been tailored. Additional content on panic has been included in the COPD programme. Symptoms of COPD and anxiety can be closely linked, and this content provides CBT-based strategies for dealing with symptoms of panic and anxiety.
The evolution of the complex immune system is equipped to defend against perilous intruders and concurrently negatively regulate the deleterious effect of immune-mediated inflammation caused by self and nonself antigens. Regulatory T-cells (Tregs) are specialized cells that minimize immune-mediated inflammation, but in malignancies, this feature has been exploited toward cancer progression by keeping the antitumor immune response in check. The modulation of Treg cell infiltration and their induction in the TME (tumor microenvironment) alongside associated inhibitory molecules, both soluble or membranes tethered in the TME, have proven clinically beneficial in boosting the tumoricidal activity of the immune system. Moreover, Treg-associated immune checkpoints pose a greater obstruction in cancer immunotherapy. Inhibiting or blocking active immune checkpoint signaling in combination with other therapies has proven clinically beneficial. This review summarizes the ontogeny of Treg cells and their migration, stability, and function in the TME. We also elucidate the Treg-associated checkpoint moieties that impede effective antitumor activity and harness these molecules for effective and targeted immunotherapy against cancer nuisance.
PROBLEM TO BE SOLVED: To provide a new oligonucleotide therapeutic agent (microRNA) relating to muscular and cardiovascular disorders.SOLUTION: A new miRNA, mir-208-2, is identified. The miRNA relates to an isolated nucleic acid molecule of less than 500 nucleotides characterized in that the isolated nucleic acid molecules comprise mir-208-2. In one embodiment, e.g. for targeting a pri-miRNA, the isolated nucleic acid molecule comprising mir-208-2 has a length of less than 200 nucleotides. In another embodiment, e.g. for targeting a pre-miRNA, the isolated nucleic acid molecule comprising mir-208-2 has a length of less than 80 nucleotides. The miRNA is used for oligonucleotide therapeutic agents (antisense oligonucleotide and/or double stranded oligonucleotide, e.g. dsRNA) and used in the treatment of muscular and cardiovascular disorders resulting from dysregulation of mir-208-2.
Patients in the 2-arm part of the study received oxaliplatin 85 mg/m\^2 intravenously (iv) + leucovorin 200 mg/m\^2 iv on Day 1 of every 2 week cycle + fluorouracil 400 mg/m\^2 bolus injection over 2 to 4 min followed by 600 mg/m\^2 continuous infusion over 22 h on Days 1 and 2 of every 2 week cycle. Patients in the 4-arm part of the study received the same treatments plus placebo for bevacizumab 5 mg/kg iv on Day 1 of every 2 week cycle.
PCT No. PCT/KR97/00055 Sec. 371 Date Aug. 2, 1999 Sec. 102(e) Date Aug. 2, 1999 PCT Filed Apr. 1, 1997 PCT Pub. No. WO97/36949 PCT Pub. Date Oct. 9, 1997A preparation method for biodegradable polymeric microspheres using a solvent extraction method for biodegradable polymeric microspheres for treating a local inflammation disease using the same which are capable of effectively curing ozena such as sinusitis and a middle ear infection. Since a non-solvent of polymer is added into an outer aqueous phase in advance, the solidification of the polymer is implemented in a short time which, in turn, improves encapsulation of the therapeutic agent used.
The study investigators will screen up to 50 Veterans undergoing right heart catheterization for clinical indications with the intention to consent up to 20 Veterans. Veterans will be screened by study investigators. Veterans who decline to consent and vulnerable populations (pregnant, incapacitated, incarcerated) will be excluded from the study.
OBJECTIVE: Aim: To predict trends in fertility, neonatal and perinatal mortality, and stillbirth rates to ascertain future perinatal care requirements during the post-war reconstruction in Ukraine.
PATIENTS AND METHODS: Materials and Methods: The study uses the data from the Centre for Medical Statistics of the Ministry of Health of Ukraine, covering the years 2012 to 2022. The data analysis was by a univariate linear regression model. The quality of these models was evaluated using the coefficient of determination, R2.
RESULTS: Results: In 2022, the birth rate in Ukraine had declined to 2.5 times lower than that of 2011. The period was characterized by a notable increase in the incidence of premature births and in neonates with birth weights under 1000 grams and between 1000 to 2499 grams. While the neonatal mortality rate decreased by 3.7 times, there remains a statistically significant (p<0.05) increase in the mortality rates of premature infants and neonates weighing less than 1000 grams. The stillbirth rate in Ukraine remains constant; however, it exceeds that of the European Union. Predictions indicate a rise in antenatal mortality and a reduction in both intranatal and perinatal mortality. As of 2022, the perinatal mortality rate in Ukraine made up 7.72 per 1000 live births, which is significantly higher than the rate in the European Union.
CONCLUSION: Conclusions: The optimization of the network of healthcare facilities and resources should be prioritized, in response to the reliable decline in the birth rate. This necessitates improvements in the medical care for premature and low birth weight infants, and efforts for preventing stillbirths.